Crossmark

Low pre-treatment neutrophil-to-lymphocyte ratio predicted a better survival in recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors

Crossref DOI link: https://doi.org/10.1007/s12672-025-02862-z

Published Online: 2025-09-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Jing

Wang, Yulu

Pei, Jiayu

Wang, Min

Wang, Dian

Guo, Ruixia

Qiu, Haifeng
Funding

Funding for this research was provided by:

Henan Province Medical Science and Technology Attack Plan Province and Ministry Joint Construction Project (SBGJ202103072)

Key Scientific Research Projects Plan of Higher Education Institutions in Henan Province (22A320011)
License Information

Text and Data Mining valid from 2025-09-29

Version of Record valid from 2025-09-29
More Information

Article History

Received: 23 November 2024

Accepted: 29 May 2025

First Online: 29 September 2025

Declarations

:

: This study was conducted at a single center (the First Affiliated Hospital of Zhengzhou University) and approved by the Institutional Ethics Review Committee at the First Affiliated Hospital of Zhengzhou University (No. 2023-KY-0461). The ethical principles of this research follow the Declaration of Helsinki. The information obtained has been signed by the patient or family members for informed consent for clinical data statistics, and it was anonymized.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below